Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autophagy-Related Disorders and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD107b/LAMP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD107b/LAMP2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled (<1 EU/ug). HEK293 Expressed for native glycosylation. Sequence Verified. |
View LAMP2 Products |
| Gene Delivery | CD107b/LAMP2 ORF Lentivirus Full-length ORF for stable cell line construction and cell-based assays. |
View LAMP2 Products |
| Benchmark Ab | Anti-CD107b/LAMP2 Recombinant Antibody Sequence-derived positive control for binding and internalization assays. |
View LAMP2 Products |
| Validator | CD107b/LAMP2 siRNA Set Target-specific knockdown verification in target-expressing cell lines. |
View LAMP2 Products |
| Related Target A | LAMP1 (CD107a) Homologous lysosomal membrane protein; essential for selectivity and counter-screening panels. |
View LAMP1 Products |
| Related Target B | GAA (Acid Alpha-Glucosidase) Key enzyme in the lysosomal pathway; relevant for Pompe disease and lysosomal storage disorder co-drugging. |
View GAA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation Dependency | HEK293 expression host ensures mammalian post-translational modifications, preserving conformational epitopes. |
| Subfamily Off-target Screening | High-purity LAMP1 and CD63 proteins available to perform rigorous selectivity profiling. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay calibration. |
| False Positives in Knockdown | Pre-designed, sequence-verified siRNA pools included for functional specificity validation. |
Live CD107b/LAMP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development surrounding CD107b/LAMP2 is bifurcated between gene therapy for monogenic disorders (such as Danon disease) and tumor-targeting modalities (ADCs and CAR-T/NK). As a major component of the lysosomal membrane, LAMP2's surface translocation in highly metastatic tumor cells makes it an attractive target for selective drug delivery. The next wave of R&D focuses on exploiting LAMP2's internalization kinetics for antibody-drug conjugates (ADCs) and targeting specific isoforms (LAMP2A, LAMP2B, LAMP2C) involved in chaperone-mediated autophagy (CMA).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Rocket Pharmaceuticals | Danon Disease (LAMP2 Deficiency) | In vitro transgene expression validation using Lentivirus-transduced control lines. |
| Antibody-Drug Conjugates (ADC) | Academic & Biopharma Consortia | Solid Tumors, Metastatic Breast Cancer | Internalization Assay (Requires high-purity ECD-Fc proteins for binding kinetics). |
| Small Molecule (CMA Modulators) | Autophagy-focused Biotechs | Neurodegenerative Diseases, Oncology | Target engagement assays using recombinant protein fragments. |